- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals
Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies like multiple myeloma and lymphomas, represent significant treatment advances, while highlighting expanding applications in solid tumors, autoimmune disorders, and infectious diseases as promising growth areas for this therapeutic modality.
EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology
EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals
EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care
EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access
EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations
EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies
EP: 7.Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology
EP: 8.Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies
EP: 9.Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy
EP: 10.Optimizing Bispecific Antibody Administration With EHR and Technology Solutions
EP: 11.Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration
EP: 12.Payer and Reimbursement Considerations for Bispecific Therapies
EP: 13.Emerging Therapeutic Areas for Bispecific Antibodies
EP: 14.Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
EP: 15.Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?
Video content above is prompted by the following:
- What are the most significant recent approvals for bispecific antibodies in oncology?
- What therapeutic areas are seeing growth in bispecific antibody applications?
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups
May 16th 2025This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Read More
